☰Menu

Actavis Receives FDA Approval of Atomoxetine HCl Capsules for ADHD

Author: Actavis Inc.
Published: 2 Sep 2010

Table of Contents:
Synopsis - Overview - Related Content

Synopsis

Actavis receives approval from FDA to market Atomoxetine HCl capsules for treatment of attention deficit hyperactivity disorder (ADHD).

Overview

Actavis has received approval from the U.S. Food & Drug Administration to market Atomoxetine HCl capsules for the treatment of attention deficit/hyperactivity disorder (ADHD).

Actavis intends to market Atomoxetine HCl in 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg strengths. No release date for Atomoxetine, Actavis' generic equivalent to Eli Lilly and Company's Strattera®, has been set. The U.S. Court of Appeals for the Federal Circuit is reviewing an Aug. 12 ruling that invalidated Lilly's patent, which is due to expire in 2017.

U.S. sales of Strattera® totaled $532 million for the 12-month period ended June 2010, according to IMS Health data.

About Actavis Inc.

Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one quarter of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis has U.S. manufacturing facilities in Elizabeth, NJ and Lincolnton, NC; and research and development facilities in Owings Mills, MD and Sunrise, FL.

About Actavis Group

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. The company has operations in 40 countries, with more than 10,500 employees.

FDA Panel Backs Galleri Multi-Cancer Early Detection Test

FDA advisory panel voted in favor of GRAIL's Galleri multi-cancer early detection test for adults 50 and older, supporting its safety and benefit-risk profile. Published: 24 Sep 2026.

Cognoa ASD Diagnosis Aid Approved for Marketing by FDA

Cognoa ASD Diagnosis Aid is an aid for diagnosis of ASD in patients 18 months - 5 years of age who are at risk of developmental delay based on concerns of a parent, caregiver, or health care provider. Published: 3 Jun 2021.

IpsiHand Brain-Computer Stroke Rehabilitation Device FDA Approved

FDA authorizes Neurolutions IpsiHand, a brain-computer interface device that uses EEG technology to help stroke patients recover hand and arm function through rehabilitation. Published: 24 Apr 2021.

Safety and Effectiveness of Consumer Hand Sanitizers

U.S. FDA completes series of actions on review of OTC antiseptic active ingredients and issues final rule on safety and effectiveness of consumer hand sanitizers. Published: 11 Apr 2019.

Permalink:

<a href="https://www.disabled-world.com/medical/pharmaceutical/fda/atomoxetine-adhd.php">Actavis Receives FDA Approval of Atomoxetine HCl Capsules for ADHD</a>: Actavis receives approval from FDA to market Atomoxetine HCl capsules for treatment of attention deficit hyperactivity disorder (ADHD).

While we strive to provide accurate, up-to-date information, our content is for general informational purposes only. Please consult qualified professionals for advice specific to your situation.

BACK TO TOP